TET2 Deficiency Sets the Stage for B-cell Lymphoma.
Cancer Discov
; 8(12): 1515-1517, 2018 12.
Article
en En
| MEDLINE
| ID: mdl-30510015
ABSTRACT
TET2 is a well-established tumor suppressor in the context of myeloid malignancies, but its role in lymphoma development has been less clear. In this issue of Cancer Discovery, Dominguez and colleagues report that TET2 function is critical for germinal center exit and plasma cell differentiation, and its deficiency can lead to B-cell lymphoma phenotypes.See related article by Dominguez et al., p. 1632.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Linfoma de Células B
/
Proteínas Proto-Oncogénicas
Límite:
Humans
Idioma:
En
Revista:
Cancer Discov
Año:
2018
Tipo del documento:
Article